PDF(Pubmed)
Abstract：
UNASSIGNED: Oxaliplatin, a platinum-based chemotherapy used in the treatment of colorectal cancer, induces acute neurotoxicity following infusion. The aim of this study was to establish whether alterations in axonal excitability develop progressively with higher cumulative doses and whether there is a recovery in motor axons after each cycle of treatment.
UNASSIGNED: Twenty consecutive patients with a colorectal cancer diagnosis, referred from the Oncology Department of Aretaieion Hospital of Athens, were enrolled in this study between October 2018 and May 2019. None of the participants had diabetes, alcohol abuse, known neuropathy or were previously treated with another neo-adjuvant therapy. Threshold Tracking techniques and Qtrac software were used for assessing axonal excitability in motor axons. Excitability recordings were undertaken before and immediately after the end of oxaliplatin infusion.
UNASSIGNED: Statistically significant changes were found (p<0.01) in axonal excitability (relative refractory period, refractoriness at 2 ms and 2.5 ms, sub-excitability and super-excitability) before and after oxaliplatin infusion. No statistically significant changes (p>0.05) were found in threshold electrotonus and strength-duration parameters before and after oxaliplatin infusion. We also did not find statistically significant differences (p>0.05) between means of excitability parameters before infusion at each cycle.
UNASSIGNED: Our study confirms oxaliplatin-induced acute neurotoxicity following infusion and suggests that motor axons recover between repeat infusion cycles.
UNASSIGNED: Twenty consecutive patients with a colorectal cancer diagnosis, referred from the Oncology Department of Aretaieion Hospital of Athens, were enrolled in this study between October 2018 and May 2019. None of the participants had diabetes, alcohol abuse, known neuropathy or were previously treated with another neo-adjuvant therapy. Threshold Tracking techniques and Qtrac software were used for assessing axonal excitability in motor axons. Excitability recordings were undertaken before and immediately after the end of oxaliplatin infusion.
UNASSIGNED: Statistically significant changes were found (p<0.01) in axonal excitability (relative refractory period, refractoriness at 2 ms and 2.5 ms, sub-excitability and super-excitability) before and after oxaliplatin infusion. No statistically significant changes (p>0.05) were found in threshold electrotonus and strength-duration parameters before and after oxaliplatin infusion. We also did not find statistically significant differences (p>0.05) between means of excitability parameters before infusion at each cycle.
UNASSIGNED: Our study confirms oxaliplatin-induced acute neurotoxicity following infusion and suggests that motor axons recover between repeat infusion cycles.
摘要：
■奥沙利铂，用于治疗结直肠癌的铂类化疗，输注后诱导急性神经毒性。这项研究的目的是确定轴突兴奋性的改变是否随着较高的累积剂量而逐渐发展，以及每个治疗周期后运动轴突是否恢复。
■连续20例诊断为结直肠癌的患者，来自雅典Aretaieion医院肿瘤科，在2018年10月至2019年5月期间参加了这项研究。参与者都没有糖尿病，酗酒,已知的神经病变或以前接受过另一种新辅助治疗。阈值跟踪技术和Qtrac软件用于评估运动轴突的轴突兴奋性。在奥沙利铂输注结束之前和之后立即进行兴奋性记录。
■轴突兴奋性（相对不应期，2ms和2.5ms时的折射，亚兴奋性和超兴奋性）在输注奥沙利铂之前和之后。在奥沙利铂输注之前和之后，阈值电张力和强度持续时间参数没有统计学上的显着变化（p>0.05）。我们也没有发现在每个周期输注前兴奋性参数的平均值之间的统计学显著差异(p>0.05)。
■我们的研究证实了输注后奥沙利铂引起的急性神经毒性，并表明运动轴突在重复输注周期之间恢复。
■连续20例诊断为结直肠癌的患者，来自雅典Aretaieion医院肿瘤科，在2018年10月至2019年5月期间参加了这项研究。参与者都没有糖尿病，酗酒,已知的神经病变或以前接受过另一种新辅助治疗。阈值跟踪技术和Qtrac软件用于评估运动轴突的轴突兴奋性。在奥沙利铂输注结束之前和之后立即进行兴奋性记录。
■轴突兴奋性（相对不应期，2ms和2.5ms时的折射，亚兴奋性和超兴奋性）在输注奥沙利铂之前和之后。在奥沙利铂输注之前和之后，阈值电张力和强度持续时间参数没有统计学上的显着变化（p>0.05）。我们也没有发现在每个周期输注前兴奋性参数的平均值之间的统计学显著差异(p>0.05)。
■我们的研究证实了输注后奥沙利铂引起的急性神经毒性，并表明运动轴突在重复输注周期之间恢复。
